PMID- 9593409
OWN - NLM
STAT- MEDLINE
DCOM- 19980610
LR  - 20220318
IS  - 0140-6736 (Print)
IS  - 0140-6736 (Linking)
VI  - 351
IP  - 9113
DP  - 1998 May 9
TI  - Circulating concentrations of insulin-like growth factor-I and risk of breast 
      cancer.
PG  - 1393-6
AB  - BACKGROUND: Insulin-like growth factor (IGF)-I, a mitogenic and antiapoptotic 
      peptide, can affect the proliferation of breast epithelial cells, and is thought 
      to have a role in breast cancer. We hypothesised that high circulating IGF-I 
      concentrations would be associated with an increased risk of breast cancer. 
      METHODS: We carried out a nested case-control study within the prospective 
      Nurses' Health Study cohort. Plasma concentrations of IGF-I and IGF binding 
      protein 3 (IGFBP-3) were measured in blood samples collected in 1989-90. We 
      identified 397 women who had a diagnosis of breast cancer after this date and 620 
      age-matched controls. IGF-I concentrations were compared by logistic regression 
      with adjustment for other breast-cancer risk factors. FINDINGS: There was no 
      association between IGF-I concentrations and breast-cancer risk among the whole 
      study group. In postmenopausal women there was no association between IGF-I 
      concentrations and breast-cancer risk (top vs bottom quintile of IGF-I, relative 
      risk 0.85 [95% CI 0.53-1.39]). The relative risk of breast cancer among 
      premenopausal women by IGF-I concentration (top vs bottom tertile) was 2.33 
      (1.06-5.16; p for trend 0.08). Among premenopausal women less than 50 years old 
      at the time of blood collection, the relative risk was 4.58 (1.75-12.0; p for 
      trend 0.02). After further adjustment for plasma IGFBP-3 concentrations these 
      relative risks were 2.88 and 7.28, respectively. INTERPRETATION: A positive 
      relation between circulating IGF-I concentration and risk of breast cancer was 
      found among premenopausal but not postmenopausal women. Plasma IGF-I 
      concentrations may be useful in the identification of women at high risk of 
      breast cancer and in the development of risk reduction strategies. Additional 
      larger studies of this association among premenopausal women are needed to 
      provide more precise estimates of effect.
FAU - Hankinson, S E
AU  - Hankinson SE
AD  - Channing Laboratory, Brigham and Women's Hospital and Harvard Medical School, 
      Boston, MA 02115, USA.
FAU - Willett, W C
AU  - Willett WC
FAU - Colditz, G A
AU  - Colditz GA
FAU - Hunter, D J
AU  - Hunter DJ
FAU - Michaud, D S
AU  - Michaud DS
FAU - Deroo, B
AU  - Deroo B
FAU - Rosner, B
AU  - Rosner B
FAU - Speizer, F E
AU  - Speizer FE
FAU - Pollak, M
AU  - Pollak M
LA  - eng
GR  - CA-40356/CA/NCI NIH HHS/United States
GR  - CA-49449/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - England
TA  - Lancet
JT  - Lancet (London, England)
JID - 2985213R
RN  - 0 (Insulin-Like Growth Factor Binding Protein 3)
RN  - 67763-96-6 (Insulin-Like Growth Factor I)
SB  - IM
CIN - Lancet. 1998 May 9;351(9113):1373-5. PMID: 9593403
CIN - Lancet. 1998 Aug 8;352(9126):488-9. PMID: 9708782
CIN - Lancet. 1998 Aug 8;352(9126):489. PMID: 9708783
CIN - Lancet. 1998 Aug 8;352(9126):489-90. PMID: 9708784
CIN - Lancet. 1998 Aug 8;352(9126):490. PMID: 9708785
MH  - Breast Neoplasms/blood/*epidemiology
MH  - Case-Control Studies
MH  - Female
MH  - Humans
MH  - Insulin-Like Growth Factor Binding Protein 3/*blood/metabolism
MH  - Insulin-Like Growth Factor I/*metabolism/physiology
MH  - Logistic Models
MH  - Middle Aged
MH  - Postmenopause
MH  - Premenopause
MH  - Prospective Studies
MH  - Risk Factors
EDAT- 1998/05/21 00:00
MHDA- 1998/05/21 00:01
CRDT- 1998/05/21 00:00
PHST- 1998/05/21 00:00 [pubmed]
PHST- 1998/05/21 00:01 [medline]
PHST- 1998/05/21 00:00 [entrez]
AID - S0140-6736(97)10384-1 [pii]
AID - 10.1016/S0140-6736(97)10384-1 [doi]
PST - ppublish
SO  - Lancet. 1998 May 9;351(9113):1393-6. doi: 10.1016/S0140-6736(97)10384-1.